ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast & Price Target

1,950 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
12Ratings
5 Buy
6 Hold
1 Sell
Based on 12 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACAD Stock Price Prediction

Average Price Target

$19.50
▲(29.05% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $19.50 with a high forecast of $25.00 and a low forecast of $12.00. The average price target represents a 29.05% change from the last price of $15.11.
Highest Price Target$25.00Average Price Target$19.50Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Guggenheim
Hold
Reiterated
FDA not planning trofinetide AdCom a positive sign for Acadia, says GuggenheimFDA not planning trofinetide AdCom a positive sign for Acadia, says Guggenheim
Morgan Stanley
$18.00
Hold
19.13%
Upside
Reiterated
Acadia Pharmaceuticals (ACAD) PT Lowered to $18 at Morgan StanleyMorgan Stanley analyst Jeffrey Hung lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $18.00 (from $22.00) while maintaining a Equalweight rating.
Citigroup
$17.00
Hold
12.51%
Upside
Reiterated
Acadia Pharmaceuticals price target raised to $17 from $15 at CitiAcadia Pharmaceuticals price target raised to $17 from $15 at Citi
Cowen & Co.
$21.00
Buy
38.98%
Upside
Reiterated
Acadia Pharmaceuticals price target lowered to $21 from $32 at CowenAcadia Pharmaceuticals price target lowered to $21 from $32 at Cowen
Oppenheimer
$19.00
Hold
25.74%
Upside
Reiterated
Acadia Pharmaceuticals price target lowered to $19 from $23 at OppenheimerAcadia Pharmaceuticals price target lowered to $19 from $23 at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ACAD Financial Forecast

ACAD Earnings Forecast
Next quarter’s earnings estimate for ACAD is -$0.24 with a range of -$0.30 to -$0.15. The previous quarter’s EPS was -$0.17. ACAD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year ACAD has Underperformed its overall industry.
Next quarter’s earnings estimate for ACAD is -$0.24 with a range of -$0.30 to -$0.15. The previous quarter’s EPS was -$0.17. ACAD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year ACAD has Underperformed its overall industry.
ACAD Sales Forecast
Next quarter’s sales forecast for ACAD is $134.50M with a range of $129.70M to $139.00M. The previous quarter’s sales results were $130.71M. ACAD beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.92% of the time in the same period. In the last calendar year ACAD has Underperformed its overall industry.
Next quarter’s sales forecast for ACAD is $134.50M with a range of $129.70M to $139.00M. The previous quarter’s sales results were $130.71M. ACAD beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 42.92% of the time in the same period. In the last calendar year ACAD has Underperformed its overall industry.
ACAD Analyst Recommendation Trends
In the current month, ACAD has received 5 Buy ratings 5 Hold ratings, and 1 Sell ratings. The ACAD average analyst price target in the past 3 months is $19.50
In the current month, ACAD has received 5 Buy ratings 5 Hold ratings, and 1 Sell ratings. The ACAD average analyst price target in the past 3 months is $19.50

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is $19.50.
    What is ACAD’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 29.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACAD a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a conensus rating of Moderate Buy which is based on 5 buy ratings, 6 hold ratings and 1 sell ratings.
            What is ACADIA Pharmaceuticals’s price target?
            The average price target for ACADIA Pharmaceuticals is $19.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $12.00. The average price target represents 29.05% Increase from the current price of $15.11.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis